Funding for this research was provided by:
Cancer Clinical Research Trust
University College Dublin
Article History
Received: 11 January 2022
Accepted: 9 April 2022
First Online: 14 July 2022
Declarations
:
: MJD and SO’G have no conflicts of interest. JC has received honoraria from Eisai, Amgen, Puma Biotechnology, Seattle Genetics, Boehringer Ingelheim, Pfizer, Vertex and Genomic Health. He has acted in an advisory/consulting role to Eisai, Puma Biotechnology, Boehringer Ingelheim, Pfizer, Vertex, Roche. He also serves on the Speakers' Bureau for Pfizer, Eisai and Genomic Health and has received Research Funding from Roche, Eisai, Boehringer Ingelheim and Puma Biotechnology. In addition, he has received travel, accommodations, expenses from MSD, Pfizer, Roche, AstraZeneca, Abbvie and Novartis. Finally, he is an employee of OncoMark, has stocks in OncoMark and is named on patent WO2020011770 (A1)—A method of predicting response to treatment in cancer patients.
: This study utilised commercially available cell lines. No human or animal subjects were used in this study.